PULM vs. ADIL, TFFP, SHPH, CVKD, ADXS, KTTA, XBIO, VCNX, CANF, and TRVN
Should you be buying Pulmatrix stock or one of its competitors? The main competitors of Pulmatrix include Adial Pharmaceuticals (ADIL), TFF Pharmaceuticals (TFFP), Shuttle Pharmaceuticals (SHPH), Cadrenal Therapeutics (CVKD), Ayala Pharmaceuticals (ADXS), Pasithea Therapeutics (KTTA), Xenetic Biosciences (XBIO), Vaccinex (VCNX), Can-Fite BioPharma (CANF), and Trevena (TRVN). These companies are all part of the "pharmaceutical preparations" industry.
Adial Pharmaceuticals (NASDAQ:ADIL) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, community ranking, dividends, earnings, institutional ownership and analyst recommendations.
16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 11.8% of Pulmatrix shares are held by institutional investors. 14.5% of Adial Pharmaceuticals shares are held by company insiders. Comparatively, 3.6% of Pulmatrix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Pulmatrix's average media sentiment score of 0.00 equaled Adial Pharmaceuticals'average media sentiment score.
Pulmatrix received 88 more outperform votes than Adial Pharmaceuticals when rated by MarketBeat users. However, 58.06% of users gave Adial Pharmaceuticals an outperform vote while only 52.27% of users gave Pulmatrix an outperform vote.
Pulmatrix has a consensus price target of $10.00, suggesting a potential upside of 429.13%. Given Adial Pharmaceuticals' higher possible upside, analysts plainly believe Pulmatrix is more favorable than Adial Pharmaceuticals.
Adial Pharmaceuticals has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.
Adial Pharmaceuticals has higher earnings, but lower revenue than Pulmatrix. Pulmatrix is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Adial Pharmaceuticals has a net margin of 0.00% compared to Adial Pharmaceuticals' net margin of -193.49%. Adial Pharmaceuticals' return on equity of -63.94% beat Pulmatrix's return on equity.
Summary
Adial Pharmaceuticals and Pulmatrix tied by winning 7 of the 14 factors compared between the two stocks.
Get Pulmatrix News Delivered to You Automatically
Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PULM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pulmatrix Competitors List
Related Companies and Tools
